- Lupin’s third-quarter revenue exceeded expectations, coming in at 57.68 billion rupees compared to an estimate of 56.83 billion rupees.
- North America sales were strong, totaling 21.21 billion rupees.
- India sales amounted to 19.31 billion rupees.
- Revenue from Europe, the Middle East, and Africa (EMEA) reached 6.25 billion rupees.
- Sales from active pharmaceutical ingredients totaled 2.89 billion rupees.
- Finance costs were higher than anticipated at 669 million rupees, compared to the estimate of 622.1 million rupees.
- Research and Development (R&D) expenses were 4.34 billion rupees, lower than the estimated 4.54 billion rupees.
- Other income stood at 537 million rupees.
- Earnings before interest, taxes, depreciation, and amortization (EBITDA) were 14.10 billion rupees, surpassing the estimated 12.83 billion rupees.
- The EBITDA margin was recorded at 25.1%.
- Currently, market analysts have placed 20 buy recommendations, 10 holds, and 7 sells for Lupin.
A look at Lupin Ltd Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 5 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Lupin Ltd shows a promising long-term outlook. With a strong score of 5 in Growth, the company is well-positioned for future expansion and development. Furthermore, Lupin Ltd scores a 4 in Resilience and Momentum, indicating its ability to withstand challenges and maintain a positive upward trend in performance. The company also scores a respectable 3 in Dividend, showing its commitment to providing returns to its shareholders. Despite a score of 2 in Value, Lupin Ltd‘s overall outlook remains positive.
Lupin Limited, a manufacturer of bulk actives and formulations, has a diversified portfolio that includes key medications such as Rifampicin, Pyrazinamide, and cardiovascular drugs. Additionally, the company specializes in phytomedicines, which are medicinal products derived from plant and herbal sources supported by modern medicine practices. This diverse product range positions Lupin Ltd well in the pharmaceutical industry, enhancing its growth prospects and overall resilience.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
